Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-24 pm EDT 5-day change 1st Jan Change
34.25 USD +1.27% Intraday chart for Collegium Pharmaceutical, Inc. +5.48% +11.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program MT
Needham Downgrades Collegium Pharmaceutical to Hold From Buy MT
Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39 MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47 MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
Transcript : Collegium Pharmaceutical, Inc., Q1 2024 Earnings Call, May 09, 2024
Collegium Announces CEO Transition CI
Collegium Announces President and Board Changes CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER CI
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes MT
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase MT
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26 MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024 CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Bond Yields Rise -2- DJ
Truist Adjusts Collegium Pharmaceutical's Price Target to $37 From $31, Keeps Buy Rating MT
Jefferies Downgrades Collegium Pharmaceutical to Hold From Buy, Raises Price Target to $37 From $30 MT
North American Morning Briefing: S&P 500 Futures Nudge Higher After Weak Start to the Year DJ
Health Care Dips on Defensive Rotation - Health Care Roundup DJ
Chart Collegium Pharmaceutical, Inc.
More charts
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
34.25 USD
Average target price
40 USD
Spread / Average Target
+16.79%
Consensus
  1. Stock Market
  2. Equities
  3. COLL Stock
  4. News Collegium Pharmaceutical, Inc.
  5. Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating